Skip to main content
Erschienen in:

Open Access 30.09.2022 | Obituary

Obituary for Herman D. Suit, M.D., D. Phil.

verfasst von: Prof. Dr. Michael Baumann, Wilfried Budach, Jürgen Debus

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 12/2022

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
“Specifically, I attribute any success that I have enjoyed is almost entirely to having been one lucky person throughout my life.” Herman Suit [1]
Herman D. Suit, M.D., D. Phil. (Fig. 1), was among the most important radiation oncologists shaping our discipline, and an honorary member of the Deutsche Gesellschaft für Radioonkologie (DEGRO). In July 2022, Dr. Suit passed away at the age of 93.
Herman Suit, born 1929 in Waco Texas, began his medical studies at Baylor Medical School in Houston at the age of 19 [2]. A summer course at the University of Texas then sparked Suit’s enthusiasm for radiation therapy, which would remain with him throughout his life [2]. He earned his D. Phil. in Radiation Oncology at the University of Oxford, where he studied the effect of radiation on the cellularity of human bone marrow, while simultaneously devoting himself to clinical oncology under another pioneer of radiotherapy, Dr. Frank Ellis [3].
Back in the USA, he initially went to the National Cancer Institute in Bethesda, Maryland, before returning to his origins in Texas in 1959. At MD Anderson Cancer Center Houston, under mentorship of Gilbert Fletcher, at that time the leader in international radiotherapy, he started to establish the principles in the treatment of soft tissue sarcomas by radiation and conservative surgery rather than amputation. In Houston, he also developed the Fletcher–Suit applicator for intracavitary radiation for women with cervical and endometrial cancer and, moreover, established one of the most important mouse colonies in the world [3].
In 1970, Herman Suit joined Harvard Medical School as Professor of Radiation Oncology, and in 1971, he also became Head of Radiation Medicine at Massachusetts General Hospital, where he later held the Andres Soriano Professorship of Radiation Oncology [4].
Hermans Suit’s lifetime achievements cannot be overstated. Always a strict advocate of scientific rigor (“you are not here to prove your idea, you are here to thoroughly investigate it”) and evidence (“what is the data?”), he was a visionary striving to move things forward. His laboratory work was vastly important in understanding the mechanisms governing the radiation response of tumors and normal tissues. Dr. Suit used his wide radiobiological and clinical knowledge to advance the safe and successful use of radiation therapy, whether through judicious fractionation, radiation doses based on tumor volume and type, shrinking fields, or the integration of radiation with surgery or chemotherapy. He also was an advocate of pushing anatomical precision of radiotherapy to its limits, not least to keep the risk of secondary tumor induction by radiotherapy as low as possible. In this context, he was one of the pioneers of making proton beam therapy a clinical reality [2, 3]. However, his most widely known contribution to the general field oncology will remain his seminal work ensuring that soft tissue sarcomas, which could previously only be radically operated on, are today equally or even more successfully treated with combination therapies—with limbs being spared [3]. Dr. Suit lifelong passion for science was fueled by his wish to make therapies better for patients. This patient-centered ethos and empathic personality was experienced by anybody who worked with him in clinics or designed research programs for which Dr. Suit regularly queried the potential impact for clinical care.
Dr. Suit was also very active in serving our community in leadership positions, for example as president of the Radiation Research Society or the American Society of Therapeutic Radiation Oncology (ASTRO). Herman Suit’s achievements were recognized, for example, with the Gold Medal of ASTRO and the American College of Radiology, and the Charles Kettering Award from the General Motors Cancer Research Foundation. In Germany, he received the Roentgen Medal in 2001 and was made an Honorary Member of DEGRO in 2002 [5, 6].
During his time at MGH, Dr. Suit hosted many young talents from all over the world. National borders played no role for him, he recruited the brightest minds wherever he could find them. He was a devoted and outstanding mentor, a role model in scientific integrity and ambition, and a life-long fatherly friend, following with great interest the careers of his former trainees of whom many later became leading international radiation oncologists and radiation researchers [3].
His special love, however, was his wife Joan Suit, also a fervent scientist and pioneer in the field of bacterial genetics. The two shared a passion for theater and music, which they always felt obliged to pass on to others, for example by regularly giving front row theater and ballet tickets to their trainees. And the Suits were always extremely generous in other ways, too, for example by inviting trainees from abroad and their families for social events at their home (particularly the famous Thanksgiving parties) and contributing to the establishment of the Herman and Joan Suit Professorship in Radiation Oncology at the Massachusetts General Cancer Center [3, 7]. Joan Suit died in 2021 at the age of 90. Now Herman Suit has succeeded her. We will keep him in our memories as a wonderful clinician and scientist, and friend.
Michael Baumann, Heidelberg
Wilfried Budach, Düsseldorf
Jürgen Debus, Heidelberg
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.
download
DOWNLOAD
print
DRUCKEN

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Jetzt e.Med zum Sonderpreis bestellen!

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Radiologie

Kombi-Abonnement

Mit e.Med Radiologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Radiologie, den Premium-Inhalten der radiologischen Fachzeitschriften, inklusive einer gedruckten Radiologie-Zeitschrift Ihrer Wahl.

Strahlentherapie und Onkologie

Print-Titel

•Übersichten, Originalien, Kasuistiken

•Kommentierte Literatur aus der Radioonkologie, Strahlenbiologie und -physik

Literatur
1.
Zurück zum Zitat Suit H (2011) A personal philosophy of a radiation oncologist. Radiother Oncol 100:10–14CrossRefPubMed Suit H (2011) A personal philosophy of a radiation oncologist. Radiother Oncol 100:10–14CrossRefPubMed
7.
Zurück zum Zitat Herman and Joan Suit Professorship in Radiation Oncology 2001 (2004) In President and Fellows of Harvard College (2004) Harvard University History of Named Chairs: Sketches of Donors and Donations 1991–2004, Cambridge, Massachusetts, pp 578–579 Herman and Joan Suit Professorship in Radiation Oncology 2001 (2004) In President and Fellows of Harvard College (2004) Harvard University History of Named Chairs: Sketches of Donors and Donations 1991–2004, Cambridge, Massachusetts, pp 578–579
Metadaten
Titel
Obituary for Herman D. Suit, M.D., D. Phil.
verfasst von
Prof. Dr. Michael Baumann
Wilfried Budach
Jürgen Debus
Publikationsdatum
30.09.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 12/2022
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-022-02004-2

Weitere Artikel der Ausgabe 12/2022

Strahlentherapie und Onkologie 12/2022 Zur Ausgabe

Neu im Fachgebiet Onkologie

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.